Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody

The coming of age of engineered multivalent antibodies

(2015) Natalia Nuñez-Prado et al.   DRUG DISCOVERY TODAY

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody

(2015) Stephen W. Jarantow et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bispecific antibodies with native chain structure

(2014) Romain Rouet et al.   NATURE BIOTECHNOLOGY

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

(2014) Steven M Lewis et al.   NATURE BIOTECHNOLOGY

Bispecific antibodies rise again

(2014) Ken Garber   NATURE REVIEWS DRUG DISCOVERY

Mind the gap

(2013) Janine Schuurman et al.   METHODS

Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering

(2013) Thomas Spreter Von Kreudenstein et al.   METHODS

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies

(2013) Brian D. Harms et al.   METHODS

MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

(2013) J. B. Fitzgerald et al.   MOLECULAR CANCER THERAPEUTICS

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Tunable Coarse-Grained Model for Ligand-Receptor Interaction

(2013) Teresa Ruiz-Herrero et al.   PLoS Computational Biology

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

(2012) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

(2012) T. Nakagawa et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose

(2011) Amrita V. Kamath et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Rational engineering of antibody therapeutics targeting multiple oncogene pathways

(2011) Jonathan Fitzgerald et al.   mAbs

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Affinity and Avidity in Antibody-Based Tumor Targeting

(2009) Stephen I. Rudnick et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

(2009) T. Yamada et al.   CLINICAL CANCER RESEARCH

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

(2008) M K Robinson et al.   BRITISH JOURNAL OF CANCER

Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities

(2008) Jessica Plati et al.   JOURNAL OF CELLULAR BIOCHEMISTRY